Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
Phase 1UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Hepatocellular Carcinoma
Conditions
Advanced/Metastatic Hepatocellular Carcinoma
Trial Timeline
Jan 25, 2021 → Oct 30, 2022
NCT ID
NCT04665362About Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib is a phase 1 stage product being developed by Sun Pharmaceutical for Advanced/Metastatic Hepatocellular Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04665362. Target conditions include Advanced/Metastatic Hepatocellular Carcinoma.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Hepatocellular Carcinoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04665362 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Advanced/Metastatic Hepatocellular Carcinoma